[The world's first Reba® subcutaneous auto-injection pen for home treatment is approved in China] On September 3, Eisai China announced that the Reba® (lencanezumab) subcutaneous auto-injection pen has been officially approved by the National Medical Products Administration for the initial treatment of early Alzheimer's disease.这是继7月该注射笔在美国获批后，中国成为全球第二、亚洲首个获批该注射笔使用的国家。 Anti-amyloid monoclonal antibody drugs, represented by lencanezumab injection, have ended the dilemma of no breakthrough progress in the field of Alzheimer's disease treatment for more than 30 years and brought a critical turn for early-stage patients to delay the course of the disease.此次新型注射笔的获批，标志着中国阿尔茨海默病治疗迈向居家管理新阶段。